 Compugen Ltd. NASDAQ: CGEN, a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration has cleared the investigational new drug IND application for its Phase 12 study evaluating the triple combination of COM701, Compugens first-in-class anti-PVRIG antibody, Opdivo nivolumab, Bristol Myers Squibbs PD-1 immune checkpoint inhibitor and BMS-986207, Bristol Myers Squibbs investigational anti-TIGIT antibody, in patients with advanced solid tumors. 